Generic name: REVEFENACIN 175ug in 3mL
Dosage form: inhalation solution
Drug class: Anticholinergic bronchodilators
Medically reviewed by Drugs.com. Last updated on May 3, 2022.
The recommended dosage is 175 mcg YUPELRI (one 175 mcg unit‑dose vial) administered by oral inhalation once daily by nebulizer using a mouthpiece.
YUPELRI should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor (See Instructions for Use). The safety and efficacy of YUPELRI have been established in clinical trials when administered using the PARI LC® Sprint nebulizer with a mouthpiece and the PARI Trek® S compressor. The safety and efficacy of YUPELRI delivered from non‑compressor based nebulizer systems have not been established.
The YUPELRI unit-dose vial should only be removed from the foil pouch and opened IMMEDIATELY BEFORE USE. The vial and any residual content should be discarded after use.
No dosage adjustment is required for geriatric patients, or patients with renal impairment [see Use in Specific Populations (8.5, 8.7) and Clinical Pharmacology (12.3)].
The drug compatibility (physical and chemical), efficacy, and safety of YUPELRI when mixed with other drugs in a nebulizer have not been established.
Frequently asked questions
More about Yupelri (revefenacin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Side effects
- During pregnancy
- FDA approval history
- Drug class: anticholinergic bronchodilators
- En español
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.